Allos Therapeutics, Inc. Announces Closing of Public Offering

WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced the closing of its previously announced underwritten public offering of 14,000,000 shares of newly issued common stock at a public offering price of $7.10 per share. The Company received net proceeds from the sale of the shares, after underwriting discounts, commissions and estimated offering expenses, of approximately $93.0 million. Allos has also granted the underwriters a 30-day option to purchase up to an aggregate of 2,100,000 additional shares of common stock to cover over-allotments, if any. Allos currently anticipates using the net proceeds of the offering primarily for activities relating to the commercialization of FOLOTYN™ (pralatrexate injection), preclinical research and clinical development of FOLOTYN, and for general corporate purposes.